NOTV - Inotiv, Inc. Stock Price, Fair Value and News

$4.15+0.25 (+6.41%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NOTV Price Action

Last 7 days

3.5%

Last 30 days

118.0%

Last 90 days

165.8%

Trailing 12 Months

32.9%

NOTV RSI Chart

NOTV Valuation

Market Cap

100.9M

Price/Earnings (Trailing)

-1.02

Price/Sales (Trailing)

0.2

EV/EBITDA

-5.75

Price/Free Cashflow

7.04

NOTV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NOTV Fundamentals

NOTV Revenue

Revenue (TTM)

501.1M

Rev. Growth (Yr)

-32.82%

Rev. Growth (Qtr)

-11.13%

NOTV Earnings

Earnings (TTM)

-99.2M

Earnings Growth (Yr)

-1.5K%

Earnings Growth (Qtr)

45.74%

NOTV Profitability

EBT Margin

-22.74%

Return on Equity

-54.48%

Return on Assets

-12.81%

Free Cashflow Yield

14.2%

NOTV Investor Care

Shares Dilution (1Y)

0.86%

Diluted EPS (TTM)

-3.83

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	552.7M	501.1M	0	0
2023	597.3M	582.2M	572.4M	585.2M
2022	277.5M	427.3M	547.7M	586.2M
2021	68.2M	75.3M	89.6M	155.9M
2020	54.6M	59.5M	60.5M	65.4M
2019	33.0M	36.5M	43.6M	49.1M
2018	23.0M	23.2M	26.3M	29.6M
2017	22.7M	23.5M	24.2M	23.4M
2016	21.4M	20.3M	20.4M	21.7M
2015	24.0M	24.1M	22.7M	21.7M
2014	23.2M	23.7M	24.6M	24.2M
2013	24.7M	23.1M	22.1M	22.5M
2012	31.1M	29.8M	28.2M	26.5M
2011	31.0M	32.1M	33.1M	32.6M
2010	0	0	28.8M	29.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Inotiv, Inc.

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment, Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services including, computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes, general and genetic toxicology, regulated bioanalysis, biotherapeutics, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes, nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

CEO	Mr. Robert W. Leasure Jr.
WEBSITE	inotivco.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	2099

Inotiv, Inc. Frequently Asked Questions

What is the ticker symbol for Inotiv, Inc.? What does NOTV stand for in stocks?

NOTV is the stock ticker symbol of Inotiv, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inotiv, Inc. (NOTV)?

As of Mon Dec 02 2024, market cap of Inotiv, Inc. is 100.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NOTV stock?

You can check NOTV's fair value in chart for subscribers.

Is Inotiv, Inc. a good stock to buy?

The fair value guage provides a quick view whether NOTV is over valued or under valued. Whether Inotiv, Inc. is cheap or expensive depends on the assumptions which impact Inotiv, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NOTV.

What is Inotiv, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 02 2024, NOTV's PE ratio (Price to Earnings) is -1.02 and Price to Sales (PS) ratio is 0.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NOTV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Inotiv, Inc.'s stock?

In the past 10 years, Inotiv, Inc. has provided 0.056 (multiply by 100 for percentage) rate of return.